Treadwell Therapeutic's Novel Acute Myeloid Leukemia Treatment Granted FDA Orphan Drug Designation

Ocifisertib is a first-in-class, novel PLK4 inhibitor that has demonstrated significant activity as a monotherapy in both solid and liquid tumors.

Source link
#Treadwell #Therapeutic039s #Acute #Myeloid #Leukemia #Treatment #Granted #FDA #Orphan #Drug #Designation